Skip to main content

Table 1 Sociodemographic, clinical and laboratory characteristics at the start of second line ART

From: Incidence and predictors of early loss to follow up among patients initiated on protease inhibitor-based second-line antiretroviral therapy in southwestern Uganda

Characteristic, N = 924 Missing n (%)  
Age in years, mean (SD) 38.4 ±  (10.5)
Female gender n (%) 518 (56.1)
Transfer in 242 (26.2)
Baseline CD4 cells/mm3 median (IQR) 97 (10) 95 (48–195)
Baseline CD4 categories
 < 100 97 (10) 433 (52.4)
 100–250   256 (31)
 251–500   100 (12.1)
 > 500   38 (4.6)
BMI in kg/m2 mean (SD) 240 (25.9) 21.6 (4.4)
Viral load (copies/ml) median (IQR) 483 (52.3) 35,500 (11,294–1,189,000)
Baseline lymphocyte count median (IQR) 310 (33.6) 1.2 (1–1.9)
Baseline Hemoglobin (g/dl), mean ±  (SD) 149 (16.1) 12.8 ± 2.1
Switch criteria n (%)
Clinical failure 96 (10.4) 256 (30.9)
 Immunological failure   307 (37.1)
 Virological failure   264 (31.9)
Marital status n (%)
 Single 58 (6) 424 (49)
 Married   442 (51)
 Employed n (%) 74 (8) 753 (81.8)
Self-reported Poor Adherence status, n (%) 799 (86.5)
Alcohol Intake, n (%) 482 (52.2)  
 Yes   119 (24.7)
 No   363 (75.3)
First Line ART Backbone, n (%)   
D4T or DDI based   357 (38.8)
AZT and3TC based   418 (45.4)
3TC and TDF - 146 (15.8)
Firstline ART Start Year
 < 2006 24 444 (49.3)
 2006–2010   278 (30.9)
 > 2010   178 (19.8)
History of opportunistic infections
 Kaposi’s Sarcoma   33 (28.1)
 Cryptococcal meningitis   10 (8.7)
 Tuberculosis 73 (63.2)
HIV staging
 1 56 (6.1) 382 (44)
 2   177 (20.4)
 3   195 (22.5)
 4   114 (13.1)